News Related to OCU410

Related coverage linked through entity extraction aliases.

Ocugen Reports Phase 2 Data for Geographic Atrophy Gene Therapy OCU410

Mar 24, 2026

Ocugen reported Phase 2 data for its geographic atrophy gene therapy OCU410 showing 31% lesion growth reduction versus control. The company plans Phase 3 initiation in Q3 2026 and maintains its goal of three BLA filings in three years. Shares fell 11.48% following the data release which trailed earlier interim results.

Ocular Therapeutix's Axpaxli Outperforms Eylea in Wet AMD Trial

Mar 24, 2026

Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.